-

Bruce Booth is a Partner at Atlas Venture focused on helping start and fund emerging biotech therapeutics companies. He's married to a wonderful woman and has three great kids. Active skier, runner, fly fisherman.
-
subscribe by email
twitter
- Debunking 6 Myths About Biotech Venture Capital. Using data to confront a few misperceptions plus other observations http://t.co/CUVdhbTSv8 14 hours ago
- MRK $5B stock buyback. R there not better uses? Acq things like Instagram & Tumblr 2 improve R&D visualization & micro-blogging study repts? 1 day ago
Recent Posts
current comments
- k bosley on Debunking Myths About Biotech Venture Capital
- Jay Caplan on Debunking Myths About Biotech Venture Capital
- Stokeley_N_Tess on Debunking Myths About Biotech Venture Capital
- Michael D'Ecclessis on Debunking Myths About Biotech Venture Capital
- Jens Eckstein on Debunking Myths About Biotech Venture Capital
topics
- Atlas Venture (2)
- Biotech financing (11)
- Biotech investment themes (13)
- Biotech startup advice (8)
- Boston Cluster (7)
- Capital efficiency (13)
- Diagnostics (2)
- Exits IPOs M&As (30)
- General Venture Capital (26)
- New business models (14)
- Personalized Medicine (2)
- Pharma industry (23)
- Portfolio news (10)
- Translational research (3)
- Uncategorized (12)
- VC-backed Biotech Returns (34)
Monthly Archive
- May 2013 (4)
- April 2013 (2)
- March 2013 (4)
- February 2013 (1)
- January 2013 (3)
- December 2012 (3)
- November 2012 (4)
- October 2012 (3)
- September 2012 (4)
- August 2012 (3)
- July 2012 (3)
- June 2012 (4)
- May 2012 (3)
- April 2012 (2)
- March 2012 (3)
- February 2012 (3)
- January 2012 (6)
- December 2011 (4)
- November 2011 (4)
- October 2011 (3)
- September 2011 (4)
- August 2011 (3)
- July 2011 (4)
- June 2011 (4)
- May 2011 (5)
- April 2011 (8)
- March 2011 (10)
Monthly Archives: February 2013
Lessons Learned: Reflections On Early Stage Biotech Venture Investing
February 8, 2013
Venture capital is often called an apprenticeship business in large part because experience matters and takes time to accumulate. But successful firms are able to translate and transfer experiential wisdom through institutional memory, which involves codifying what works and what



